James F. Reddoch, EVP, Research & Investments at Royalty Pharma plc (RPRX), sold 250,000 shares at $44.60 ($11.4M) on 2021-06-04, disclosed to the SEC on 2021-06-08.
Open-market sale of $11.4M RPRX by EVP, Research & Investments. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.60 | 100,000 | $4.5M | 39.0% |
| 2 | $46.57 | 47,790 | $2.2M | 19.5% |
| 3 | $46.57 | 47,790 | $2.2M | 19.5% |
| 4 | $47.01 | 2,210 | $104K | 0.9% |
| 5 | $47.01 | 2,210 | $104K | 0.9% |
| 6 | $46.43 | 50,000 |
| $2.3M |
| 20.3% |
| Total | $45.76 avg | 250,000 | $11.4M | 100% |
| Filing → |
| RPRX | SELL | 2022-05-31 | $3.1M | — | Filing → |
| RPRX | SELL | 2022-05-23 | $3.0M | — | Filing → |
| RPRX | SELL | 2021-07-27 | $712K | — | Filing → |